DXS InternationalSTU:7EE 39 Days Payable is 94.51 as of Apr. 2025, which is 38% below its 10-year median of 152.15. GuruFocus rates STU:7EE with a GF Score™ of 39/100 and a GF Value™ of €0.02. The stock has 2 warning signs investors should review. Among 605 Healthcare Providers & Services companies, DXS International ranks better than 67.77% on this metric.
The historical rank and industry rank for DXS International's Days Payable or its related term are showing as below:
STU:7EE'
s Days Payable Range Over the Past 10 Years
Min: 94.49 Med: 152.15 Max: 239.71
Current: 94.49
During the past 11 years, DXS International's highest Days Payable was 239.71. The lowest was 94.49. And the median was 152.15.
STU:7EE's Days Payable is ranked better than 67.77% of 605
companies
in the Healthcare Providers & Services industry
Industry Median: 57.51
vs STU:7EE: 94.49
DXS International's Days Payable
declined
from Apr. 2023 (107.78) to Apr. 2025 (94.51).
It may suggest that DXS Internationalaccelerated paying its suppliers.
DXS International Days Payable Related Terms
DXS International Days Payable Historical Data
* Premium members only.
The historical data trend for DXS International's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:7EE vs VEEV, BTSG, TEM: Days Payable Comparison
For the Health Information Services subindustry, DXS International's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DXS International Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DXS International's Days Payable distribution charts can be found below:
* The bar in red indicates where DXS International's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
DXS International's Days Payable for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DXS International (STU:7EE) has a Days Payable of 94.51 as of Apr. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DXS International and its competitors. This is 38% below median its historical median of 152.15. Over the past decade, DXS International's Days Payable has ranged from 94.49 to 239.71. According to the industry distribution chart, DXS International ranks #195 out of 605 companies in the Healthcare Providers & Services industry, placing it in the top 32.2%.
Is DXS International's Days Payable too high?
DXS International's current Days Payable of 94.51 is 38% below median its 10-year median of 152.15. Over the past 10 years, this metric has ranged from a low of 94.49 to a high of 239.71. The Healthcare Providers & Services industry median Days Payable is 57.51. DXS International's value of 94.51 is 64.3% above this industry median. Based on the distribution chart, DXS International ranks #195 out of 605 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DXS International has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does DXS International's Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DXS International ranks #195 out of 605 companies for Days Payable. This puts DXS International in the upper half of its industry. The industry median Days Payable is 57.51. DXS International's value of 94.51 is 64.3% above this benchmark. Historically, DXS International's own Days Payable has ranged from 94.49 to 239.71 over the past decade. While the company's 10-year median is 152.15 vs. the industry median of 57.51, DXS International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.51, based on 605 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DXS International's current Days Payable of 94.51 is 64.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on DXS International and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DXS International's current Days Payable is 94.51, which is 38% below median its own 10-year median of 152.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DXS International stock overvalued right now?
DXS International (STU:7EE) has a current Days Payable of 94.51. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 45% below its estimated fair value. The current Days Payable is 94.51, which is 38% below median its 10-year median of 152.15 and 64.3% above the Healthcare Providers & Services industry median of 57.51. DXS International's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For DXS International (STU:7EE), the current Days Payable is 94.51 as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DXS International (STU:7EE) Overvalued in 2026?
Based on GuruFocus' analysis, DXS International stock appears to be undervalued.
The current stock price of €0.01 is trading 45% below its estimated GF Value™ of €0.02.
Key valuation signals for STU:7EE:
Days Payable: 94.51 (38% below median its 10-year median of 152.15)
GF Value™: €0.02 vs. price of €0.01 (45% below fair value)
Industry Position: 64.3% above the Healthcare Providers & Services median (#195 of 605)
No single metric tells the full story. See the STU:7EE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DXS International PLC is engaged in the development and distribution of clinical decision support systems for General Practitioners, nurses, and retail pharmacies in the United Kingdom and South Africa. Its commercial activities include licensing DXS products to various ICBs, offering e-detailing opportunities to the pharmaceutical industry and the UK primary care sector, and licensing its technology to healthcare publishers. The company's products include BestPathway and Point-of-Care ExpertCare.
39GF Score
Get the complete analysis for STU:7EE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:7EE has been successfully added to your 
